Dynamics of gastric acid inhibition by ranitidine in duodenal ulcer patients.
The dynamics of the inhibitory effect of ranitidine, a new H2-receptor antagonist, on histamine and pentagastrin-induced gastric secretion have been examined in duodenal ulcer patients. The inhibition by ranitidine of histamine-induced secretion was found to be competitive, whereas that of pentagastrin-induced secretion not competitive. Ranitidine was an effective inhibitor of pentagastrin-induced secretion for 8-12 h after administration. The availability of ranitidine, a powerful and long-acting inhibitor of gastric secretion, provides an opportunity of an alternative treatment from cimetidine for peptic ulcer and related diseases.
D000328:Adult; D001667:Binding, Competitive; D004305:Dose-Response Relationship, Drug; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000378:metabolism*; D005663:Furans / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism*; D006632:Histamine / Q000494:pharmacology; D006635:Histamine H2 Antagonists; D006801:Humans; D008297:Male; D010418:Pentagastrin / Q000494:pharmacology; D011899:Ranitidine; D013997:Time Factors
D005663:Furans; D006635:Histamine H2 Antagonists; D006632:Histamine; D011899:Ranitidine; D010418:Pentagastrin